Where does Mesoblast, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mesoblast, Inc. ranks #11,731 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mesoblast, Inc. hold?

Mesoblast, Inc. holds 26 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Mesoblast, Inc.'s Innovation Score?

Mesoblast, Inc. has an Innovation Score of 30.5 out of 100 (35th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Mesoblast, Inc.'s patent grant rate increasing or decreasing?

Mesoblast, Inc.'s recent grant velocity is -74% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Mesoblast, Inc.'s patents?

Mesoblast, Inc.'s patents average 16.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mesoblast, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Mesoblast, Inc.

Q: What technology areas does Mesoblast, Inc. focus on?

Mesoblast, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 26 patents, ranking #417 of 4,144 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 26 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mesoblast ranks #11,731 of 49,997 tracked US assignees by granted-patent volume, with 26 patents across 7 technology areas.

#11,731
of 49,997 US assignees by volume: 35th percentile
by Innovation Score (30.5/100): 16.3
avg claims per patent: -74%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11731 · US Corporation #11,731 · 26 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 26 grants
UPPER-Q #11,731/49,997
PHOTO-FINISH Lexion Medical
CPC-NARROW C12N · 7 areas
INNOV-THIN 30.5/100
CLAIMS-RICH 16.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -74% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lexion Medical, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Mesoblast’s 30.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.4 pts (37%) Velocity 0.0 pts (0%) Breadth 9.4 pts (31%) Claim depth 9.8 pts (32%)

Qualcomm Incorporated · highest

85
Shilpa Medicare · near

31
BIG Lift · near

31
Mesoblast · this assignee

31
Nakanishi · near

31
Rfaxis · near

31
3D Lighting… · lowest

7

What this shows Mesoblast's Innovation Score is 30.5/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Mesoblast?

Each dot is one of Mesoblast’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mesoblast’s own 16.3 claims/patent is ABOVE the 15.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Mesoblast vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Mesoblast's grants concentrate

Mesoblast, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2016 (7 grants) versus a trough of 1 in 2017. By volume, Mesoblast sits between Lexion Medical, LLC and MOJ.IO, Inc..

Lexion Medical

26
Macauto Industrial

26
Macom Connectivit…

26
MAS Innovation (P…

26
Millennial Media

26
Mitralign

26
Mitsubishi Plasti…

26
MOJ IO

26
Mesoblast ◀

26

What this shows Mesoblast holds 26 patents at rank #11,726, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mesoblast

By rank, the assignees closest to #11,726 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Mesoblast's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mesoblast, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Mesoblast ranks #417 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (31 here).

Nakanishi Inc. 31 BIG Lift, LLC 31 Rfaxis, Inc. 31 Shilpa Medicare Limited 31

Mesoblast's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 35th percentile higher than 35% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mesoblast, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	11.5%
2016	7	26.9%
2017	1	3.8%
2018	5	19.2%
2019	3	11.5%
2020	4	15.4%
2021	1	3.8%
2025partial year	2	7.7%

Which technologies does Mesoblast, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 26

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 24

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C07K - Peptides 2

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Mesoblast, Inc.'s patent record in context - here's where to go next.

Mesoblast, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #11,731 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mesoblast, Inc. against Lexion Medical, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.